FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:2000-2001 June 24, 1999 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Tugwell, P. Related Article by Weinblatt, M. E.

To the Editor: The study by Weinblatt et al. (Jan. 28 issue)¹ attempts to demonstrate the efficacy of combined therapy with methotrexate and etanercept through a randomized, double-blind trial. This study design is powerful, but a prerequisite is that the patients assigned to treatment and those assigned to placebo must have equal probabilities of achieving the primary end point — in this case, the American College of Rheumatology criteria for a 20 percent improvement in measures of disease activity.

Weinblatt et al. do not report the functional class of the patients, as defined by the American College of Rheumatology, in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Yanik, G. A., Ho, V. T., Levine, J. E., White, E. S., Braun, T., Antin, J. H., Whitfield, J., Custer, J., Jones, D., Ferrara, J. L. M., Cooke, K. R. (2008). The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 112: 3073-3081 [Abstract] [Full Text]